1423 related articles for article (PubMed ID: 31362073)
1. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
Saleh R; Elkord E
Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
[TBL] [Abstract][Full Text] [Related]
2. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
3. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
4. Overcoming tumor-mediated immunosuppression.
Schlößer HA; Theurich S; Shimabukuro-Vornhagen A; Holtick U; Stippel DL; von Bergwelt-Baildon M
Immunotherapy; 2014; 6(9):973-88. PubMed ID: 25341119
[TBL] [Abstract][Full Text] [Related]
5. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
6. Combining epigenetic and immune therapy to overcome cancer resistance.
Gomez S; Tabernacki T; Kobyra J; Roberts P; Chiappinelli KB
Semin Cancer Biol; 2020 Oct; 65():99-113. PubMed ID: 31877341
[TBL] [Abstract][Full Text] [Related]
7. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
8. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
9. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
10. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoints in the tumor microenvironment.
Toor SM; Sasidharan Nair V; Decock J; Elkord E
Semin Cancer Biol; 2020 Oct; 65():1-12. PubMed ID: 31265893
[TBL] [Abstract][Full Text] [Related]
12. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
Huo S; Liu L; Li Q; Wang J
Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
15. Differentiation and Regulation of T
Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
Front Immunol; 2021; 12():669474. PubMed ID: 34012451
[TBL] [Abstract][Full Text] [Related]
16. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
Weng CY; Kao CX; Chang TS; Huang YH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
18. Tumor hypermetabolism confers resistance to immunotherapy.
Liu A; Curran MA
Semin Cancer Biol; 2020 Oct; 65():155-163. PubMed ID: 31982512
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]